LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

Home・Elenco Azioni・Roivant Sciences Ltd

Roivant Sciences Ltd

Chiusa

SettoreSettore sanitario

29.88 1.22

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

29.15

Massimo

29.98

Metriche Chiave
By Trading Economics
Entrata	669M 356M
Vendite	521K 2.5M
Margine di Profitto	14,116.825
Dipendenti	721
EBITDA	-65M -354M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+27.89% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	1.3B 21B
Apertura precedente	28.66
Chiusura precedente	29.88

Notizie sul Sentiment di mercato

By Acuity

24%

76%

37 / 344 Classifica in Healthcare

Roivant Sciences Ltd Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 mag 2026, 21:33 UTC

Utili

Correction to Salesforce 1Q Sales, Profit Rise Article

27 mag 2026, 21:00 UTC

Acquisizioni, Fusioni, Takeovers

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 mag 2026, 20:18 UTC

Utili

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 mag 2026, 23:49 UTC

Discorsi di Mercato

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 mag 2026, 23:39 UTC

Discorsi di Mercato

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 mag 2026, 23:34 UTC

Discorsi di Mercato

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 mag 2026, 23:34 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

27 mag 2026, 23:08 UTC

Discorsi di Mercato

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 mag 2026, 22:21 UTC

Discorsi di Mercato

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 mag 2026, 21:29 UTC

Azioni calde

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 mag 2026, 21:08 UTC

Utili

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 mag 2026, 21:02 UTC

Utili

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 mag 2026, 20:59 UTC

Acquisizioni, Fusioni, Takeovers

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 mag 2026, 20:55 UTC

Utili

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 mag 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

27 mag 2026, 20:48 UTC

Utili

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 mag 2026, 20:45 UTC

Utili

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 mag 2026, 20:34 UTC

Acquisizioni, Fusioni, Takeovers

Webster Financial Stockholders Approve Sale to Banco Santander

27 mag 2026, 20:32 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 mag 2026, 20:32 UTC

Acquisizioni, Fusioni, Takeovers

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 mag 2026, 20:32 UTC

Acquisizioni, Fusioni, Takeovers

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 mag 2026, 20:30 UTC

Utili

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 mag 2026, 20:30 UTC

Acquisizioni, Fusioni, Takeovers

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 mag 2026, 20:22 UTC

Utili

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mag 2026, 20:16 UTC

Utili

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mag 2026, 20:13 UTC

Utili

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 mag 2026, 20:13 UTC

Utili

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 mag 2026, 20:13 UTC

Utili

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 mag 2026, 20:12 UTC

Utili

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 mag 2026, 20:12 UTC

Utili

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Confronto tra pari

Modifica del prezzo

Roivant Sciences Ltd Previsione

Obiettivo di Prezzo

By TipRanks

27.89% in crescita

Previsioni per 12 mesi

Media 37.83 USD 27.89%

Alto 42 USD

Basso 31.5 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Roivant Sciences Ltd - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Roivant Sciences Ltd - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

37 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.